source
- China clamps down on investigator-initiated biotech trials after patient deaths, halting rare-disease studiesChinese regulators have introduced new rules that sharply limit investigator‑initiated biotech trials after a series of patient deaths were reported this summer. The policy shift is intended to tig…
- Alethio Therapeutics secures $90 million to develop treatments for rare blood cancersAlethio Therapeutics, a UK based biotechnology startup, announced it has raised $90 million in new financing. The capital will be used to advance its pipeline targeting myeloproliferative neoplasm…